GeoVax Labs (GOVX) Video Presentation.
GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers the possibility...
PharmaTher (PHRRF) Breaks Above Resistance.
We're now up 325% in just Under a Year. Last "big" News was Receiving a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)...
Ardelyx (ARDX) Firmly Above Resistance.
Were not traders and we don't do technical analysis, but we could see this coming from a mile away. Next stop $9.00 and then...
Continued Strength at LQR House (LQR) Post-Reverse Split.
Like a Surprise Christmas Gift, LQR House has Gained Nearly Four-Fold (330%) Post Split. New Report out Tomorrow.
LIVE QUOTE
LQR House News Archive
Well, this...
Five Myths About Ketamine and Matthew Perry’s Death (Fox News).
Through the first nine months of the year, global Johnson and Johnson's Spravato Ketamine nasal-spray revenues were $483 million, an 88.8% increase over the...
LQR House (LQR) +65%, Rebounding On New Clients Announcements.
The Liquor House Continues to Impress.
We called this the most interesting Company of 2023. While extreme volume and volatility remains unabated, we're now...
We’re Up 35% in Paramount.
Market Cap Increases $3 Billion Since Adding to Watch List on October 23rd. And That's a Lot of Money!
Adding Paramount (PARA) $12 to the...
Two That Doubled and Now Look Ready to Break Out.. and a Third That...
We are up 234% in Ardelyx (ARDX) $5.23 since adding it to Watch List a year ago and up 71% in Cardiol Therapeutics (CRDL)...
Tharimmune (THAR) Announces Positive Topline “Itching” Data.
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Phase 1 ex-US trial in chronic liver...
Hundreds of Stocks Have Fallen Below $1. They’re Still Listed on Nasdaq. (WSJ)
Investor-protection advocates say many belong to risky small companies that should be on the OTC market.
With 557 names listed, the real problem, too many...














